Antioxidants 11 , 1817 (2022)
[Google Scholar] Oche, O
These factors individually and/or synergistically result in cellular death, including apoptosis, autophagy, and necroptosis (9, 10, 13)
%3F)
AASLD: Hepatitis Debrief: The Liver Meeting 2018 - (11/19/18) HBV Therapies in Development - (11/15/17) Drugs in Development for Hepatitis B 2017 - Compounds in Development for Chronic Hepatitis B - Updated January 2019 AASLD: Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Patients with Chronic Hepatitis B - (02/13/19) AASLD: FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV - (02/13/19) AASLD: First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV - (02/13/19) AASLD: TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients - (02/13/19) AASLD: Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (02/13/19) AASLD: Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNin patientswithchronicHBV/HDV co-infection - (02/13/19) AASLD: PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY: RESULTS FROM THE PROSPECTIVE DARING-B STUDY - (01/02/19) AASLD: KINETICS OF SERUM HEPATITIS B CORE RELATED ANTIGEN (HBcrAg) IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) PATIENTS WHO DISCONTINUE EFFECTIVE LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) - (01/02/19) AASLD: Safety, Pharmacokinetics, and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients With Chronic Hepatitis B: a Randomized, Placebo-Controlled, Double-blind Phase 1b Study - (12/31/18) AASLD: No Resistance to Tenofovir Alafenamide Detected Through 144 Weeks of Treatment in Patients With Chronic Hepatitis B - (12/31/18) AASLD: 3-Year Efficacy and Safety of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in HBeAg-Negative and -Positive Patients With Chronic Hepatitis B - (12/31/18) AASLD: Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate - (12/31/18) AASLD: Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort - (12/17/18) AASLD: Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) - (12/17/18) AASLD: In Vitro Antiviral Activity and Mode of Action of JNJ-64530440, a Novel Potent Hepatitis B Virus Capsid Assembly Modulator in Clinical Development - (12/17/18) AASLD: ALT levels and risk of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients under long-term therapy with entecavir or tenofovir disoproxil fumarate - (12/17/18) AASLD: Early adoption of tenofovir alafenamide (TAF) for Hepatitis B in US clinical practice
This is achieved through oxidative damage to pathogen membranes
